---

COMMUNITY MEDICINE PAPER - I: COMPLETE ANSWERS

---

SECTION - I

---

Q.1 - Structured Long Question

Q.1 (1) - National Tuberculosis Elimination Programme (NTEP) [2+4+4 = 10 marks]

A. Objectives of NTEP (2 marks)

1. To achieve a case detection rate of >85% of all new sputum positive TB cases
2. To achieve a treatment success rate of >90% under DOTS
3. To reduce TB incidence by 80% and TB mortality by 90% (compared to 2015 baseline)
4. To ensure zero catastrophic expenditure for TB-affected families by 2030
5. To actively find, treat and support all TB patients - including drug-resistant TB

B. Diagnostic Strategy under NTEP (4 marks)

1. Presumptive TB identification - Any person with cough ≥2 weeks, fever, weight loss, night sweats, or any person with HIV is designated as "presumptive TB."
2. Upfront Molecular Testing (CBNAAT/TrueNat):
   • All presumptive TB cases should be tested using CBNAAT (Cartridge Based Nucleic Acid Amplification Test) or TrueNat at the first point of contact
   • These tests simultaneously detect TB and rifampicin resistance
   • TrueNat - a chip-based real-time PCR test (portable, can be used at sub-district level)
3. Sputum Smear Microscopy (SSM): Used where molecular tests are not available; ZN stain (Ziehl-Neelsen) for AFB. Two spot sputum samples collected.
4. Culture and Drug Sensitivity Testing (DST):
   • Liquid culture (MGIT) - gold standard, results in 2-6 weeks
   • Solid culture (LJ medium) - 6-8 weeks
   • First-line and second-line DST done for drug-resistant TB
5. X-Ray chest: Supportive, not diagnostic alone
6. CBNAAT for all: All diagnosed TB patients should have CBNAAT for rifampicin resistance testing
7. Line Probe Assay (LPA): For detection of resistance to isoniazid, fluoroquinolones (Hain's test)
8. Universal Drug Susceptibility Testing (UDST): All bacteriologically confirmed TB patients must undergo DST

• DS-TB: 2HRZE + 4HR (daily fixed-dose combination therapy)
• MDR-TB: Bedaquiline-based regimen (BPaL, BPaLM) - shorter 6-month regimen now adopted
• All patients enrolled on Nikshay portal (online notification mandatory)
• Nikshay Poshan Yojana: Rs. 500/month direct benefit transfer to TB patients for nutrition

C. Public Health Measures for TB Elimination (4 marks)

1. Case Detection:
   • Active Case Finding (ACF) - door-to-door screening in high-risk areas (slums, prisons, tea garden workers)
   • Universal Drug Susceptibility Testing
   • Notification of all TB cases (private sector mandatory under Gazette notification 2012)
   • Ni-kshay: IT-enabled TB notification system
2. TB Preventive Treatment (TPT):
   • Isoniazid preventive therapy (IPT) for all household contacts of TB patients
   • 6H (6 months isoniazid) or 3HP (3 months isoniazid + rifapentine weekly) regimens
   • TPT for all HIV-positive individuals (regardless of TST)
3. BCG Vaccination:
   • Universal BCG at birth under UIP - protects against severe childhood TB (miliary TB, TBM)
4. Infection Control:
   • Airborne infection control guidelines (HEPA filters, UV lamps, N95 masks in health facilities)
   • Patient education on cough etiquette
5. Social Determinants:
   • Ni-kshay Poshan Yojana (nutritional support - Rs. 500/month)
   • Pradhan Mantri TB Mukt Bharat Abhiyan (PMTBMBA) - community engagement, Ni-kshay Mitra (volunteers/NGOs support patients)
   • Targeted screening of vulnerable populations (miners, migrants, diabetics, malnourished)
6. Private Sector Engagement:
   • Mandatory notification, free diagnostic and treatment support for private sector patients
7. Monitoring & Evaluation:
   • Quarterly cohort analysis
   • Treatment outcome tracking on Nikshay

---

Q.1 (2) - Assessment of Nutritional Status and Community-Based Interventions [5+5 = 10 marks]

A. Methods of Assessment of Nutritional Status in Under-Five Children (5 marks)

• SAM (Severe Acute Malnutrition): Weight for height <-3 SD OR MUAC <11.5 cm OR bilateral pitting edema (kwashiorkor)
• MAM (Moderate Acute Malnutrition): WHZ between -2 and -3 SD

• Grade I: 75-90% of expected weight
• Grade II: 60-74%
• Grade III: <60%

• 24-hour dietary recall
• Food frequency questionnaire
• Diet history

• A - Anthropometric (above)
• B - Biochemical: Serum albumin (<3.5 g/dL = deficiency), hemoglobin (anemia), serum ferritin, serum retinol (Vitamin A), urinary iodine concentration
• C - Clinical signs: Kwashiorkor (edema, moon face, flag sign, dermatosis), marasmus (skin and bones, loose folds of skin), vitamin A deficiency (Bitot spots, xerophthalmia), rickets (wrist widening, rachitic rosary)
• D - Dietary/developmental assessment

• IMR, under-5 mortality rate, low birth weight rates

B. Community-Based Interventions to Improve Nutritional Status (5 marks)

1. ICDS (Integrated Child Development Services):
   • Supplementary nutrition (SNP) for children 6 months to 6 years
   • Anganwadi Centres (AWCs) - 3.4 lakh centers across India
   • Health check-up, immunization, referral services, pre-school education, nutrition & health education
2. POSHAN Abhiyan (National Nutrition Mission, 2018):
   • Aims to reduce stunting, wasting, underweight, and anemia
   • Target: Reduce stunting by 2% per year, wasting by 2% per year
   • Convergence of multiple programs, monthly POSHAN Diwas (Suposhan Diwas)
3. Mid-Day Meal Scheme (now PM POSHAN):
   • Hot cooked meals for school children
   • Improves enrollment, attendance, retention
4. Vitamin A Supplementation Programme:
   • Massive doses at 9 months, 16 months, then every 6 months up to 5 years
   • Universal Immunization Programme (UIP) linked
5. Iron and Folic Acid (IFA) Supplementation:
   • Anaemia Mukt Bharat - iron syrup for children 6-59 months
   • Bi-weekly IFA in school under Weekly Iron and Folic Acid Supplementation (WIFS) programme
6. Management of SAM at Community Level:
   • Community-based Management of Acute Malnutrition (CMAM)
   • Ready-to-Use Therapeutic Food (RUTF) for uncomplicated SAM
   • Nutrition Rehabilitation Centers (NRC) for complicated SAM
7. Growth Monitoring and Promotion (GMP):
   • Monthly weighing at AWC
   • Road-to-health chart / growth monitoring card
8. Promotion of Exclusive Breastfeeding:
   • For 0-6 months; complementary feeding from 6 months
   • Mother's Absolute Affection (MAA) programme
9. Deworming:
   • National Deworming Day (Feb 10 and Aug 10) - Albendazole 400 mg single dose for 1-19 years
10. WASH interventions:
    • Clean water, sanitation, hygiene to break the malnutrition-infection cycle

---

Q.2 - Case Based Scenarios (Any 2 out of 3)

Q.2 (1) - Rabies: Animal Bite Categorization and Post-Exposure Prophylaxis [3+3 = 6 marks]

A. WHO Categorization of Animal Bite Exposures

B. Intra-Dermal Rabies Vaccination Schedule for PEP

• Approved schedules:
  • Updated Thai Red Cross (TRC) 2-2-2-0-2: ID at 2 sites on Days 0, 3, 7, 28
  • New abbreviated 2-ID regimen (WHO 2018): 2 ID sites on Day 0 and Day 3 (for Category II with prior vaccination - 2 doses only)

• Updated TRC schedule: 0.1 mL ID at 2 sites (both deltoids or deltoid + thigh) on Days 0, 3, 7, 28
• Volume per ID: 0.1 mL (vs 0.5-1.0 mL IM)
• Vaccine used: Cell culture vaccines (PVRV - Purified Vero cell rabies vaccine, or PCECV)
• Advantages of ID route: Less vaccine used, cost-effective, equally immunogenic

• Human RIG (HRIG): 20 IU/kg body weight
• Equine RIG (ERIG): 40 IU/kg body weight
• Injected infiltrated around the wound; remaining given IM at distant site
• Must be given on Day 0 or as soon as possible, not after Day 7

---

Q.2 (2) - HIV in Pregnancy: PMTCT and NACP Role [3+3 = 6 marks]

A. Public Health Measures to Prevent Mother-to-Child Transmission (PMTCT) of HIV

• ART for the mother (Option B+): Lifelong ART for all HIV-positive pregnant women regardless of CD4 count or clinical stage - TLE regimen (Tenofovir + Lamivudine + Efavirenz)
• Start ART as early as possible (ideally in first trimester)
• ART reduces viral load to undetectable = prevents transmission
• Mode of delivery: Elective LSCS preferred if viral load >1000 copies/mL; normal delivery if viral load undetectable
• Intrapartum: IV Zidovudine if VL unknown/high
• Infant prophylaxis: Nevirapine syrup for 6 weeks to baby after birth
• Feeding: Exclusive breastfeeding for 6 months with maternal ART OR exclusive formula feeding (if safe, affordable, feasible) - WHO recommends breastfeeding with ART in resource-limited settings

• Universal HIV testing at first ANC visit (ICTC/PPTCT services)
• Partner testing and counseling
• Disclosure support
• CD4 count and viral load monitoring

B. Role of National AIDS Control Programme (NACP) in This Case

1. ICTC (Integrated Counselling and Testing Centre):
   • Provides free HIV testing at all ANCs/government hospitals
   • Counseling before and after test
   • This woman would have been detected at ICTC linked to her ANC
2. PPTCT (Prevention of Parent-to-Child Transmission) Programme:
   • Enrolls HIV-positive pregnant women
   • Provides free ART (TLE regimen) for life (Option B+)
   • Provides NVP prophylaxis to newborn
   • Follows up infant for HIV testing at 6 weeks (DNA PCR), 18 months (antibody test)
3. ART Centre:
   • Long-term management of the mother
   • CD4 monitoring, viral load testing
   • Opportunistic infection prophylaxis (Co-trimoxazole prophylaxis)
4. Link Worker Scheme / ASHA: Follows up patients at community level, supports adherence
5. Blood Safety Programme: Ensures blood transfusions are safe
6. Condom distribution and STI management
7. Stigma reduction campaigns - addresses psychosocial aspects of this 28-year-old

---

Q.2 (3) - 30-Year-Old Man with Hypo-Pigmented Patches: Leprosy [2+4 = 6 marks]

A. Diagnosis

1. Hypopigmented (or reddish/erythematous) skin patch(es) with definite loss of sensation
2. Thickened peripheral nerve(s) + sensory/motor deficit in distribution
3. Positive skin smear (AFB)

• PB (Pauci-Bacillary): 1-5 skin lesions, no nerve involvement, smear negative
• MB (Multi-Bacillary): >5 skin lesions, or nerve involvement, or smear positive

B. Management under National Programme (National Leprosy Eradication Programme - NLEP)

1. Case detection and registration at PHC; notification
2. Slit skin smear examination (at District Leprosy Office)
3. Contact examination - household contacts screened
4. Reaction management:
   • Type 1 (Reversal reaction): Prednisolone 40-60 mg/day, taper over 6 months
   • Type 2 (ENL - Erythema Nodosum Leprosum): Thalidomide or clofazimine or steroids
5. Disability prevention and rehabilitation:
   • MCR (Micro-cellular Rubber) footwear for insensitive feet
   • Self-care of hands and feet (soaking, oiling)
   • Reconstructive surgery if needed
6. Social rehabilitation: Under NLEP - leprosy is no ground for discrimination (Disability Act amendment)
7. Fixed Duration Treatment (FDT): MDT given free of cost through government health system

---

Q.3 - Short Notes (Any 3 out of 4)

Q.3 (1) - Consequences of Failure to Disclose Medical Errors [6 marks]

1. Loss of trust in healthcare providers and the health system
2. Denial of informed decision-making - patient cannot seek second opinions or alternative treatments
3. Delayed treatment for harm caused by the error
4. Psychological harm - patient may blame themselves for deterioration
5. Continued exposure to harm if the error-causing practice continues

1. Increased risk of litigation and malpractice suits (paradoxically, disclosure often reduces lawsuits)
2. Criminal liability in some jurisdictions
3. Disciplinary action by Medical Council

1. Missed opportunity for quality improvement - errors not analyzed cannot be prevented
2. Perpetuation of blame culture vs. just culture
3. Systemic errors go uncorrected - more patients harmed
4. Reduced staff morale and increased burnout (moral distress)

1. Violation of autonomy (patient's right to know)
2. Violation of beneficence and non-maleficence
3. Breach of veracity (truthfulness) - a core bioethical principle
4. Violates informed consent principles

1. Loss of professional credibility
2. Action by MCI/NMC - removal from register
3. Erosion of doctor-patient relationship

---

Q.3 (2) - Confounding Factor and Bias in Epidemiological Studies [6 marks]

A. Confounding Factor

1. Must be associated with the exposure (risk factor)
2. Must independently be associated with the outcome (disease)
3. Must NOT be an intermediate step in the causal pathway

• Study: Coffee drinking and lung cancer
• Apparent association: Coffee drinkers have higher lung cancer
• Confounder: Smoking - coffee drinkers are more likely to smoke, and smoking causes lung cancer
• Controlling for smoking eliminates the coffee-lung cancer association

• At design stage: Randomization, restriction, matching
• At analysis stage: Stratification (Mantel-Haenszel), multivariate analysis, propensity scoring

B. Bias

• Example: Berkson's bias - hospitalized patients used as controls; both cases and controls are hospitalized so disease associations appear distorted
• Healthy worker effect - employed workers are healthier than general population

• Recall bias: Cases (diseased) remember past exposures better than controls. Common in case-control studies. Example: Mothers of children with birth defects recall drug use during pregnancy more than mothers of healthy children
• Observer bias: Interviewer knows case status and probes differently
• Hawthorne effect: Subjects change behavior when they know they are being observed

• Publication bias - positive results more likely to be published

• Bias is a systematic error in the study method; confounding is a real but distorted true association
• Bias cannot be corrected after the study; confounding can be controlled statistically

---

Q.3 (3) - Family: Definition and Role in Health and Disease [6 marks]

A. Definition of Family

• Nuclear family (parents + children) - most common in urban India
• Extended/joint family - multiple generations under one roof
• Single-parent family
• Reconstituted/blended family

B. Role of Family in Health

1. Biological functions: Reproduction, genetic transmission of diseases (hereditary disorders)
2. Primary socialization: Health behaviors, dietary habits, hygiene practices, health beliefs are first learned in the family
3. Emotional support: Emotional security reduces psychological disorders; family support is protective against mental illness
4. Caregiving: Primary caregivers in illness, especially chronic diseases, disability, and elderly care
5. Economic function: Shared resources affect nutrition, housing, healthcare access
6. Health behavior transmission: Smoking, alcohol use, physical activity patterns are family-influenced

C. Role of Family in Disease

1. Infectious disease clustering: Communicable diseases (TB, hepatitis, skin infections) spread within households
2. Genetic diseases: Autosomal dominant (Huntington's), autosomal recessive (sickle cell, thalassemia), sex-linked disorders cluster in families
3. Lifestyle diseases: Shared diet and activity levels lead to family clustering of obesity, hypertension, type 2 diabetes
4. Mental health: Family dysfunction, domestic violence, parental mental illness affect children's mental health
5. Vulnerability periods: Family life events (divorce, death, financial crisis) are risk periods for health breakdown
6. Cultural/religious practices: Some practices are protective (vegetarianism, yoga) and some harmful (consanguinity, female genital mutilation)

• Family folder/family health record in primary care
• ICMR Family Health Survey
• Family physician/PHC doctor manages the family unit

---

Q.3 (4) - Anaemia Mukt Bharat Abhiyan: Key Interventions and 7×7×7 Strategy [6 marks]

A. Anaemia Mukt Bharat (AMB) Abhiyan

B. Key Interventions (6 target beneficiary groups)

1. Children 6-59 months: Weekly iron syrup (IFS - Iron Folic Acid Syrup)
2. Children 5-9 years: IFA pink tablets bi-weekly; bi-annual deworming
3. Adolescents 10-19 years (WIFS - Weekly Iron Folic Acid Supplementation): Weekly IFA blue tablet; bi-annual deworming; monthly peer education sessions
4. Pregnant women: Daily IFA red tablets (180 tablets over pregnancy); calcium supplementation; deworming
5. Lactating mothers: Daily IFA red tablets for 180 days postpartum
6. Women of reproductive age 20-49 years (non-pregnant, non-lactating): IFA supplementation

C. 7×7×7 Strategy of AMB

1. Prophylactic IFA supplementation
2. Deworming
3. Behaviour change communication (BCC) / IEC
4. Test, treat, and talk about anaemia
5. Delay cord clamping at birth (>3 minutes for term babies)
6. Food fortification (double fortified salt, fortified rice distribution through PDS)
7. Addressing non-nutritional causes of anaemia (malaria, hemoglobinopathies, fluorosis)

1. Health and wellness centres / Sub-centres
2. Anganwadi Centres (AWC) - ICDS
3. Schools (under Samagra Shiksha Abhiyan)
4. Primary Health Centres
5. Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) clinics
6. Village Health Sanitation and Nutrition Day (VHSND)
7. Community level (ASHA/link workers)

1. Nikshay-like IT-based monitoring system (AMB portal)
2. Supply chain management
3. Capacity building of frontline workers
4. Community mobilization
5. Convergence of government programs
6. Private sector engagement
7. Research and evidence generation

---

Q.4 - Very Short Answers (Any 5 out of 6)

Q.4 (1) - Disability-Adjusted Life Year (DALY)

• YLL (Years of Life Lost) = Number of deaths × Standard life expectancy at age of death
• YLD (Years Lived with Disability) = Number of prevalent cases × disability weight × duration

---

Q.4 (2) - Control vs. Elimination vs. Eradication

---

Q.4 (3) - One Health Approach

• Zoonotic disease control (rabies, avian influenza, Nipah, SARS-CoV-2, Brucellosis)
• Antimicrobial resistance (AMR) - antibiotics used in animals affect human pathogens
• Food safety
• Environmental health (deforestation → new zoonoses)

---

Q.4 (4) - Isolation vs. Quarantine

---

Q.4 (5) - Herd Immunity

---

Q.4 (6) - Point Source Epidemic: 2 Characteristics + Diagram

1. Explosive onset: The epidemic curve rises sharply and steeply, with a large number of cases appearing within a short time (usually within one incubation period). This is because all susceptible individuals are exposed simultaneously.
2. No secondary waves: The curve falls as rapidly as it rose, with no secondary peaks. Once the source is removed, cases stop occurring as there is no person-to-person spread (unless a propagated epidemic follows).

Number
of cases
   |
   |      ****
   |     *    *
   |    *      *
   |   *        *
   |  *          *
   | *            *
   |*              *_________
   |________________________
        Time (days)
        ↑
   Single exposure event

---

---

COMMUNITY MEDICINE PAPER - I: SECTION II - COMPLETE ANSWERS

---

Q.5 - Structured Long Question

Q.5 (1) - Screening: Definition, Criteria for Disease Selection, and Ideal Screening Test [2+4+4 = 10 marks]

A. Definition of Screening (2 marks)

• Screening is NOT diagnostic - a positive screen requires confirmatory diagnostic testing
• It is applied to asymptomatic, apparently healthy individuals
• Aim: early detection to allow early treatment and improve prognosis

• Mass screening (entire population)
• Selective/targeted screening (high-risk groups)
• Multiphasic screening (multiple tests simultaneously)
• Opportunistic/case-finding (when patient attends for other reasons)

B. Criteria for Selecting a Disease for Screening (Wilson-Jungner Criteria, 1968 - WHO) (4 marks)

1. Important health problem - the condition being screened for should be an important public health problem (high prevalence, high morbidity/mortality). Example: Cervical cancer, TB, hypertension.
2. Recognizable latent or early symptomatic stage - there must be a detectable preclinical phase (e.g., CIN [cervical intraepithelial neoplasia] precedes cervical cancer by years).
3. Natural history well understood - the progression from latent to declared disease must be known.
4. Agreed and acceptable treatment - there must be an accepted, effective treatment available for recognized disease.

C. Characteristics of an Ideal Screening Test (4 marks)

• PAP smear for cervical cancer - high sensitivity for CIN/cancer
• Mantoux test (TST) for TB infection
• Fasting blood glucose for diabetes
• Mammography for breast cancer
• PSA for prostate cancer (sensitivity ~79%, specificity ~59%)

---

Q.5 (2) - NP-NCD Objectives and CBAC Form [5+5 = 10 marks]

A. National Programme for Non-Communicable Diseases (NP-NCD) - Objectives (5 marks)

1. Prevention and health promotion - Reduce risk factors for NCDs (tobacco use, unhealthy diet, physical inactivity, harmful alcohol use) through IEC/BCC campaigns
2. Early diagnosis - Promote early detection of common NCDs through population-based screening at sub-centre and PHC level
3. Management - Provide standardized treatment and follow-up for patients at all levels of health care
4. Capacity building - Strengthen human resources (training of CHOs, ANMs, ASHAs) and infrastructure (District NCD clinics, NCD cells)
5. Referral system - Establish effective two-way referral linkages between community and tertiary care
6. Surveillance and monitoring - Strengthen NCD surveillance including risk factor surveillance (STEPS survey), morbidity and mortality data
7. Integrate with primary care - Integrate NCD services into the existing primary healthcare system (Health and Wellness Centres - HWCs under AB-HWC)

• Cardiovascular diseases (hypertension, IHD)
• Cancer (oral, breast, cervical - through NPPCCS screening)
• Diabetes mellitus (Type 2)
• Stroke
• Also includes: COPD, CKD (under expanded NCD screening)

• District NCD Clinics at District Hospital
• CHC-level cardiac care units
• NCD cells at state and district level
• Population-based screening using CBAC (see below)
• Ayushman Bharat Health and Wellness Centres (AB-HWC) as the frontline platform

• 25% reduction in premature NCD mortality by 2025
• 10% reduction in harmful alcohol use
• 30% reduction in tobacco prevalence
• Halt rise in obesity and diabetes
• 25% reduction in hypertension prevalence

B. CBAC (Community Based Assessment Checklist) Form for Early Detection of NCDs (5 marks)

• Identify adults with risk factors for NCDs
• Detect suspected cases of hypertension, diabetes, oral cancer, breast cancer, and cervical cancer
• Ensure early referral to Health and Wellness Centre / PHC for confirmation

• Name, age, sex, address, phone number

• History of high BP, headache, palpitations

• Frequent urination, excessive thirst, unexplained weight loss, slow healing wounds

• Any ulcer/swelling in mouth >3 weeks
• White/red patch in mouth
• Difficulty in chewing/swallowing
• Tobacco/betel nut use (highest risk factor)

• Lump in breast
• Nipple discharge or change in nipple shape
• Changes in breast skin
• Underarm lump

• Vaginal bleeding after intercourse, between periods, after menopause
• Foul-smelling vaginal discharge
• Pain in lower abdomen

• A score of 4 or more indicates high risk and the individual should be referred to the nearest HWC/Sub-centre/PHC for confirmation
• ASHA fills, submits to ANM, and follows up on referred individuals

• Those confirmed to have NCDs are enrolled in the NCD registry
• Provided with treatment, counseling, and follow-up at PHC/CHC

---

Q.6 - Short Notes (Any 2 out of 3)

Q.6 (1) - Confidence Interval: Concept and Interpretation [6 marks]

A. Concept

• x̄ = sample mean
• Z = Z-score for desired confidence level (1.96 for 95%, 2.58 for 99%)
• SD = standard deviation
• n = sample size

B. Interpretation in Epidemiology

• If the CI for the difference between two means includes zero, the difference is NOT statistically significant (p > 0.05)
• If the CI does not include zero, the difference IS statistically significant (p < 0.05)

• If the CI includes 1.0, the association is NOT statistically significant
• If CI is entirely above 1 → significantly increased risk
• If CI is entirely below 1 → significantly protective/reduced risk

• OR = 2.5 (95% CI: 1.8 - 3.6): Statistically significant increased risk (CI does not cross 1)
• OR = 1.3 (95% CI: 0.9 - 1.8): Not statistically significant (CI crosses 1)
• RR = 0.6 (95% CI: 0.4 - 0.85): Statistically significant protective effect

• Narrow CI → large sample size, precise estimate
• Wide CI → small sample size, imprecise estimate
• Higher confidence level (99% vs 95%) → wider interval

• CI provides more information than p-value alone
• CI shows the direction, magnitude, and precision of an estimate
• P-value only tells statistical significance, not clinical significance
• A p-value of <0.05 with a very narrow CI may indicate statistical significance but clinically trivial effect

---

Q.6 (2) - Visual Impairment, Blindness, Causes in India, and National Programme [6 marks]

A. Definitions (as per NPCBVI)

• Previous prevalence (2007 survey): 1.0% of population
• Current prevalence (National Survey 2015-19): 0.36%
• Estimated 8 million blind in India currently

B. Major Causes of Visual Impairment and Blindness in India

• Vitamin A deficiency (xerophthalmia, corneal scarring)
• Congenital cataract and rubella
• Retinopathy of prematurity (ROP)
• Corneal ulcers

C. Prevention and Control under National Programme (NPCBVI)

1. Cataract Surgery:
   • Free cataract operations at government hospitals (IOL implantation)
   • National target: 6.6 million cataract surgeries per year
   • District Mobile Ophthalmic Units (for camps in rural areas)
   • Eye banks for corneal transplantation
2. School Eye Screening:
   • Annual eye examination of school children (Classes 1-8)
   • Free spectacles to children with refractive errors
   • Referral for amblyopia, strabismus, childhood cataract
3. Glaucoma Control:
   • Screening camps for IOP measurement
   • Free medications (latanoprost, timolol eye drops) at government centres
4. Diabetic Retinopathy:
   • Fundus screening for diabetic patients at NCD clinics
   • Laser photocoagulation at district/tertiary hospitals
5. Vitamin A Supplementation:
   • Under UIP - prevents childhood blindness due to VAD
   • Universal supplementation for 9 months to 5 years (doses every 6 months)
6. VISION 2020: The Right to Sight (India):
   • Global WHO initiative adopted by India
   • Focus on cataract, refractive errors, trachoma, childhood blindness, onchocerciasis
7. Human Resources:
   • Training of ophthalmic assistants, vision technicians
   • Mid-level ophthalmic personnel (MLOP)
8. Infrastructure:
   • Dedicated ophthalmic wards at district hospitals
   • 3-tier referral: Sub-centre → PHC → CHC/District Hospital → Medical College

---

Q.6 (3) - Telemedicine in Public Health [6 marks]

A. Types of Telemedicine

1. Synchronous (real-time): Video consultation, phone consultation - live interaction
2. Asynchronous (store-and-forward): Patient data, images, reports sent for later review by specialist (e.g., teleconsultation for ECG, X-ray reading, dermatology images)
3. Remote patient monitoring: Wearable devices, glucometers, BP monitors transmitting data

B. Applications in Public Health

1. Bridging rural-urban healthcare gap:
   • Specialist consultation available to remote PHC/sub-centre
   • eSanjeevani - National teleconsultation platform (launched 2019) - over 25 crore consultations by 2024
2. Disease surveillance and outbreak response:
   • Real-time reporting of outbreak data
   • IDSP (Integrated Disease Surveillance Programme) uses IT/telemedicine infrastructure
   • Remote coordination during COVID-19 pandemic
3. NCD management:
   • Remote BP/blood glucose monitoring
   • Telecardiology (ECG transmission from PHC to cardiologist)
   • Diabetic retinopathy screening (fundus image to ophthalmologist)
4. Maternal and child health:
   • Remote fetal monitoring (CTG transmission)
   • High-risk pregnancy monitoring from PHCs
5. Mental health:
   • Tele-MANAS (National Mental Health Programme's teleconsultation service)
   • Reduces stigma associated with in-person visits
6. TB management:
   • 99DOTS (digital adherence technology) - missed dose alerts via mobile phone
   • Video-observed treatment (VOT) as alternative to directly observed treatment (DOT)
7. Training and capacity building:
   • CME and in-service training via telemedicine for PHC doctors and nurses

C. Advantages

• Reduces geographic barriers to care
• Cost-effective (reduces patient travel and hospitalization)
• Reduces load on tertiary care hospitals
• Continuity of care for chronic diseases
• Useful during disasters, pandemics (as demonstrated by COVID-19)

D. Challenges and Limitations

• Digital divide - lack of internet connectivity, digital literacy in rural areas
• Infrastructure requirements (reliable broadband, devices)
• Patient privacy and data security concerns
• Limitations in physical examination
• Medicolegal issues (liability, prescription rules)
• Regulatory challenges - not all states have uniform implementation

---

Q.7 - Short Notes (Any 3 out of 4)

Q.7 (1) - Legislation for Prevention of Tobacco-Related Disease [6 marks]

A. Global Framework

• First international public health treaty negotiated under WHO auspices
• India ratified in 2004 (entered into force 2005)
• Provides the framework for comprehensive tobacco control

• M - Monitor tobacco use and prevention policies
• P - Protect people from tobacco smoke (smoke-free places)
• O - Offer help to quit tobacco use (cessation services)
• W - Warn about dangers of tobacco (health warnings on packs)
• E - Enforce bans on advertising, promotion and sponsorship
• R - Raise taxes on tobacco products

B. Indian Legislation

• Complete ban on e-cigarettes and ENDS (Electronic Nicotine Delivery Systems) in India

• Launched 2007-08
• Activities: IEC campaigns (World No Tobacco Day - May 31), tobacco cessation clinics (TCC) at district hospitals, training of healthcare providers
• Tobacco Cessation Centres: 0.2 mg/2 mg nicotine gum, bupropion, varenicline available

• Several states have additional laws: Goa, Madhya Pradesh, Maharashtra, Himachal Pradesh have comprehensive anti-tobacco laws
• Gusthkhi Acts, betel nut/gutkha bans (several states)

• High taxes on tobacco are considered the single most effective tobacco control measure (WHO)
• GST + Compensation Cess on cigarettes and other tobacco products in India

---

Q.7 (2) - International Health Regulations (IHR) and Traveller's Health [6 marks]

A. International Health Regulations (IHR 2005)

1. Core Capacity Requirements: Countries must develop, strengthen, and maintain core capacities for surveillance, reporting, notification, verification, response, and collaboration at points of entry (ports, airports, ground crossings)
2. Event assessment: Notify WHO of any event that may constitute a Public Health Emergency of International Concern (PHEIC)
3. PHEIC declaration: WHO Director-General can declare a PHEIC (examples: SARS 2003, H1N1 2009, Polio 2014, Ebola 2014/2019, Zika 2016, COVID-19 2020, Mpox 2022)

• Criteria for PHEIC declaration (Annexure 2 - decision instrument)
• Core capacity requirements for points of entry
• Health documents (vaccination certificates, Maritime Declaration of Health, etc.)

• International Certificate of Vaccination and Prophylaxis (ICVP/Yellow Card): Proof of Yellow Fever vaccination (required for travel to/from endemic countries)
• Meningococcal vaccine certificate (required for Hajj/Umrah pilgrims)

B. Traveller's Health

• Mandatory vaccines:
  • Yellow fever (travel to Africa, South America endemic countries)
  • Meningococcal ACWY (Hajj/Umrah pilgrims - Saudi Arabia requirement)
• Recommended vaccines:
  • Typhoid, Hepatitis A (low-income destinations)
  • Hepatitis B (if not vaccinated)
  • Japanese encephalitis (Southeast Asia)
  • Rabies pre-exposure (adventure travellers, veterinary workers)
  • Cholera (oral vaccine in endemic areas)

• Chloroquine for sensitive regions
• Atovaquone-proguanil (Malarone), Doxycycline, or Mefloquine for resistant regions

• "Boil it, cook it, peel it, or forget it"
• Oral rehydration salts, ciprofloxacin/azithromycin for treatment

• Insect bite prevention (DEET repellent, long-sleeved clothing, bed nets)
• Sun protection, altitude sickness prevention (acetazolamide for high altitude)
• Safe sex practices (STI, HIV)
• DVT prevention on long flights (hydration, compression stockings, leg exercises)
• Travel insurance and location of nearest hospital

• Fever within 3 months of return from malaria-endemic area = malaria until proved otherwise
• Report to travel medicine clinic / IDSP centre if symptomatic

---

Q.7 (3) - Preparedness and Response to Biological Emergencies (Bioterrorism) [6 marks]

A. Definition

B. Classification of Biological Agents (CDC Categories)

C. Detection and Surveillance

• Syndromic surveillance: Automated detection of unusual disease clusters (e.g., sudden increase in pneumonia, hemorrhagic fever, rash illness in unusual age groups)
• Laboratory sentinel network: Designated labs (BSL-3, BSL-4) for confirmation
• Epidemiological clues for bioterrorism attack:
  • Unusual clustering of disease
  • Disease out of season or geographic range
  • Unusual route of exposure (e.g., inhalational anthrax)
  • Multiple simultaneous outbreaks
  • Unusual pathogen or antibiotic resistance patterns

D. Preparedness

1. National preparedness plans:
   • India's National Disaster Management Plan (NDMP) covers biological threats
   • Ministry of Health Emergency Operations Centre (EOC)
   • IDSP for disease surveillance
2. Medical countermeasures:
   • Strategic stockpiling of antibiotics, antivirals, antitoxins
   • Smallpox vaccine stockpile (WHO-coordinated)
   • Pre-positioned PPE (personal protective equipment)
3. Laboratory infrastructure:
   • BSL-3 labs: National Institute of Virology (NIV), Pune; NICD, Delhi
   • High-throughput PCR for rapid pathogen identification
4. Training:
   • First responders (police, fire, ambulance) trained in CBRN (Chemical, Biological, Radiological, Nuclear) response
   • Healthcare worker training in recognition and barrier nursing

E. Response

1. Immediate response (First 24 hours):
   • Identification and notification (IDSP/EOC)
   • Isolation and quarantine of cases and contacts
   • Epidemiological investigation (field teams)
   • Sampling and specimen transport to reference labs
2. Short-term response:
   • Mass prophylaxis (antibiotics for anthrax exposure - ciprofloxacin 60 days)
   • Decontamination of affected area
   • Communication with public - prevent panic (risk communication)
3. Long-term:
   • Vaccination programs if vaccine available
   • Psychosocial support
   • Environmental remediation

---

Q.7 (4) - Operational Research in Community Medicine [6 marks]

A. Definition

B. Characteristics

• Takes place within operational/program settings (not controlled laboratory settings)
• Focuses on program performance problems
• Results are intended to directly inform decisions by program managers
• Usually quick turnaround, low cost
• Does not generate new scientific knowledge but applies existing knowledge to improve delivery

C. Types of Operational Research Questions (DOPE framework)

D. Methods Used

• Surveys, interviews, focus group discussions
• Cohort analysis (treatment outcome studies)
• Case-control studies within program settings
• Before-after (pre-post) comparisons
• Cross-sectional studies

E. Examples in Community Medicine

1. TB (NTEP): Study of reasons for default (loss to follow-up) in DOTS patients at a PHC in rural Maharashtra → identified transportation cost and work loss as key barriers → mobile DOTS camps introduced
2. Immunization: Study of drop-out rates between DPT-1 and DPT-3 in an urban slum → identified session timing mismatch with working mothers → immunization sessions extended to evenings
3. PMTCT (NACP): Study of loss-to-follow-up of HIV-positive pregnant women after diagnosis at ICTC → identified lack of partner support as a barrier → male partner counseling introduced
4. Malaria: Study of bed net usage rates in a tribal district despite distribution → found non-use due to heat and discomfort → lighter mesh nets procured
5. Nutrition: Evaluation of ICDS supplementary nutrition utilization rates → found cooking at home reduced acceptance of take-home rations → revised caloric density formulations

F. Importance of OR in Community Medicine

• Bridges the gap between evidence and practice ("know-do gap")
• Helps tailor national programs to local realities
• Low cost and rapid compared to basic research
• Directly improves program performance
• Builds local research capacity
• Required for program scale-up and replication

---

Q.8 - Very Short Answers (Any 5 out of 6)

Q.8 (1) - Cluster Sampling Method

1. Define the population and divide into clusters (natural groupings - villages, wards, schools)
2. Randomly select a number of clusters using SRS or PPS (probability proportional to size)
3. Study all (or a sample of) members within selected clusters

• Single-stage cluster: All elements in selected clusters are included
• Two-stage cluster: Random sample from within selected clusters
• Multi-stage: Further sub-sampling

• India divided into administrative areas (tehsils)
• 30 clusters selected by PPS
• 7 children under 5 selected from each cluster
• Total sample = 210 children
• Used to estimate vaccination coverage nationally

---

Q.8 (2) - Screening Tests for Colorectal or Cervical Cancer

1. Fecal Occult Blood Test (FOBT) - guaiac-based or FIT (Fecal Immunochemical Test) - annually
2. Sigmoidoscopy (flexible) - every 5 years
3. Colonoscopy - every 10 years (gold standard for detection and polypectomy)
4. Double contrast barium enema - every 5 years (less sensitive)
5. CT Colonography (Virtual Colonoscopy) - every 5 years
6. Stool DNA test (Cologuard) - every 1-3 years

1. PAP smear (Conventional cytology) - every 3 years (ages 21-65); most widely used
2. Liquid-Based Cytology (LBC) - improved PAP smear, every 3 years
3. HPV DNA test (High-Risk HPV Testing) - every 5 years (ages 30-65); tests for HR-HPV types 16, 18, 31, 33, 45 etc.
4. Co-testing (PAP + HPV) - every 5 years (ages 30-65)
5. VIA (Visual Inspection with Acetic Acid) - in low-resource settings, immediate results; ANM-administered
6. VILI (Visual Inspection with Lugol's Iodine) - similar to VIA
7. Colposcopy - diagnostic (not screening), for abnormal PAP/VIA

---

Q.8 (3) - Type II Error

• β = P (Type II error) = P (accepting H₀ | H₀ is false)
• Power of a study = 1 - β = probability of correctly detecting a true difference

• Small sample size (most common)
• High variability in the data
• Small effect size (the true difference is real but small)
• α set too strictly (too low)

---

Q.8 (4) - Four Vaccines Covered under the Open Vial Policy (OVP)

1. OPV (Oral Polio Vaccine) - multi-dose vial, OVP applies; can be stored for 28 days after opening if kept at 2-8°C
2. DPT (Diphtheria, Pertussis, Tetanus) - liquid formulation vials
3. TT (Tetanus Toxoid) / Td - multi-dose vials
4. Hepatitis B vaccine (monovalent) - multi-dose vials

• Cold chain maintained (2-8°C)
• Sterile technique used during reconstitution
• VVM (Vaccine Vial Monitor) has not reached discard point
• Vial not expired
• No visible contamination

---

Q.8 (5) - Primary Prevention (Modes of Intervention) for Oral Cancer

• Tobacco use (smoking + smokeless/chewing) - most important
• Alcohol use (synergistic with tobacco)
• Betel nut/areca nut use (including gutka, pan masala)
• HPV infection (especially HPV-16, -18) - oropharyngeal cancer
• Poor oral hygiene, ill-fitting dentures (chronic trauma)
• Sun exposure (lip cancer)
• Nutritional deficiencies (Vitamin A, C, iron)

1. Tobacco cessation:
   • COTPA enforcement (bans on sale to minors, tobacco-free zones near schools)
   • Tobacco cessation clinics (brief counseling - 5 As: Ask, Advise, Assess, Assist, Arrange)
   • Pictorial health warnings on tobacco packs (85% of pack surface)
   • Nicotine Replacement Therapy (NRT): nicotine gum, patch; pharmacotherapy: bupropion, varenicline
   • Taxation on tobacco (price increase reduces consumption)
2. Alcohol reduction:
   • Regulatory restrictions on alcohol sales
   • Counseling using AUDIT (Alcohol Use Disorders Identification Test) + brief intervention
3. Betel nut/gutka ban:
   • Several states have banned gutka/pan masala under Food Safety Act
   • Awareness campaigns
4. HPV vaccination:
   • Gardasil-9 or Cervarix (HPV 16/18) for adolescent girls (and boys) - also protects against oropharyngeal HPV cancers
   • Under national programme: HPV vaccine launched in NIP (National Immunization Programme) for girls 9-14 years in 2023
5. Nutritional interventions:
   • Adequate intake of fruits and vegetables (antioxidants)
   • Correction of iron deficiency anaemia (Plummer-Vinson syndrome predisposes to oral cancer)
6. Health education and IEC:
   • Awareness about early warning signs (SORE mnemonic: Sore that doesn't heal, Odd patch/lump, Red or white patch, Eating/swallowing difficulty)
   • School health education programs
   • Village health nutrition days
7. Oral hygiene:
   • Regular brushing, dental check-ups
   • Removal of ill-fitting dentures

---

Q.8 (6) - Four Ethical Principles of Biomedical Research

1. Respect for Autonomy (Non-maleficence):
   • Individuals have the right to make informed decisions about their own participation in research
   • Operationalized through Informed Consent (IC) - voluntary, comprehension, disclosure, capacity
   • Protects vulnerable groups (children, prisoners, mentally incapacitated)
   • Allows participants to withdraw at any time without penalty
2. Beneficence:
   • Research should aim to maximize benefits to participants and society
   • Obligation to "do good" - the research should have scientific value and potential to improve health outcomes
   • Includes favorable risk-benefit ratio assessment
3. Non-maleficence:
   • "First, do no harm" (Primum non nocere)
   • Minimize risks and harms to research participants
   • Research risks must be justified by anticipated benefits
   • Covers physical, psychological, social, and economic harms
4. Justice:
   • Fair distribution of the burdens and benefits of research
   • No exploitation of vulnerable or disadvantaged populations
   • Selection of participants should be equitable - do not select the poor/marginalized only for risky studies while wealthy benefit
   • Includes distributive justice (fair allocation) and procedural justice (fair process)

• Confidentiality - participant data protected
• Scientific validity - only valid, well-designed studies are ethical
• Independent ethics review (IEC/IRB) - Institutional Ethics Committee approval mandatory
• ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) - the Indian standard

---